Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth
The Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
Noemi Lois is a Clinical Professor of Ophthalmology at Queens University and an Honorary Consultant Ophthalmologist and Vitreoretinal Surgeon at the Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK. After having obtained her medical degree, Noemi did her Residency in Ophthalmology in Spain and then completed clinical fellowships in 1) Ocular Oncology at Wills Eye Hospital, Philadelphia, with Drs Jerry and Carol Shields, 2) Medical Retina at Moorfields Eye Hospital, London, with Prof Alan Bird, and 3) Vitreoretinal Surgery at The Royal Liverpool University Hospital with Prof David Wong. Noemi then moved to Aberdeen, Scotland, where she worked as full time Consultant Ophthalmic Surgeon for 13 years and then joined Queens in 2013 where she has been leading a programme of preclinical and clinical research focused on diabetic retinopathy and its complications (diabetic macular oedema and proliferative diabetic retinopathy). This programme of research extends from pathogenic mechanisms of disease and risk stratification to new therapies, including determining the most cost-effective therapeutic alternatives for this disease. The value of Noemi’s current active grants (competitive public or charity funding) as principal applicant or co-applicant is over £3 million. Noemi has published over 100 articles in peer review journals (Scopus h-index 33), 13 book chapters and is editor of 3 textbooks, one on its second edition; is ad-hoc referee for numerous peer-review journals and funding bodies and has given numerous lectures as guest speaker at national and international meetings in China, India, Indonesia, Ireland, Italy, Malaysia, Singapore, South Africa, Switzerland, USA and the UK. Noemi is editorial board member for several journals including the Cochrane Eyes and Vision Group.
Noemi has participated, as a member of the Evidence Review Group, in 10 Single Technology Appraisals for the UK National Institute of Health and Care Excellence (NICE) on new therapies for eye diseases.